The terminal sugar molecules of the N-linked glycan attached to the fragment crystalizable (Fc) region is a critical quality attribute of therapeutic monoclonal antibodies (mAbs) such as immunoglobulin G (IgG). There exists naturally-occurring heterogeneity in the N-linked glycan structure of mAbs, and such heterogeneity has a significant influence on the clinical safety and efficacy of mAb drugs. We previously proposed a constraint-based modeling method called glycosylation flux analysis (GFA) to characterize the rates (fluxes) of intracellular glycosylation reactions. One contribution of this work is a significant improvement in the computational efficiency of the GFA, which is beneficial for analyzing large datasets. Another contribution of our study is the analysis of IgG glycosylation in continuous perfusion Chinese Hamster Ovary (CHO) cell cultures. The GFA of the perfusion cell culture data indicated that the dynamical changes of IgG glycan heterogeneity are mostly attributed to alterations in the galactosylation flux activity. By using a random forest regression analysis of the IgG galactosylation flux activity, we were further able to link the dynamics of galactosylation with two process parameters: cell-specific productivity of IgG and extracellular ammonia concentration. The characteristics of IgG galactosylation dynamics agree well with what we previously reported for fed-batch cultivations of the same CHO cell strain.Processes 2018, 6, 176 2 of 15 and process analytical technology put further emphasis on implementing quantitative approaches for process improvements in biopharmaceutical manufacturing [4,5].Continuous manufacturing technology offers an effective and flexible way for the large scale and robust production of drug compounds [6]. In the biopharmaceutical industry, the application of continuous cell culture technology has thus far been limited to the production of unstable products that require constant recovery [7]. Nevertheless, continuous perfusion cell cultures have previously been demonstrated to be capable of producing antibodies at a volumetric rate that matches or exceeds that of fed-batch cultures [8]. In addition to the high productivity, the stable steady state operation mode in conjunction with the short residence time of perfusion cultures translates to a tight maintenance of product quality. Whether or not product qualities and their key controlling parameters can be directly translated from the traditional batch/fed-batch cell cultures to the perfusion cell cultivations is still unresolved. Past work on converting mAb production from batch/fed-batch to perfusion cell cultures gave conflicting reports on product qualities, where a few studies demonstrated consistent product qualities [9,10], and many others showed differences between the two production modes [11][12][13][14][15].Among the key critical quality attributes (CQAs) of therapeutic mAbs is the glycan structures of the Fc domain [16]. The N-linked glycosylation is a common post-translational modification of proteins, ...